NEWS & Topics

2021.05.10 First patient enrolled in phaseⅢ clinical trial of TM-411 in combination with azacitidine for higher-risk MDS in US.
2021.01.12 Reached an agreement with Syros Pharmaceuticals Inc., to be granted for the Biomarker License.
2021.01.12 Reached agreement with Syros Pharmaceuticals Inc., to add the Southern America & Oceania regions in the territory in the license agreement dated Sept. 2015.
Focusing on cancer!
Business areas

Company Overview